• Who we are
Multispecific yet truly natural antibodies

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Taking next generation, multispecific antibody technologies into Alzheimer’s Disease and Antimicrobial Resistance

Who we are
Who we are

Long term pharma and biotech professionals with a track record of leading projects from research into the market

Our antibody development roots go deep

Our focus
Our focus

Multispecific yet natural

Alzheimer’s Disease and Antimicrobial Resistance

CD47 Dual targeting
Our pipeline

Fully human bi- and multi-specific antibodies for the treatment of Alzheimer’s Disease and Antimicrobial Resistant infections

Safe and selective blockade of CD47 on tumors

Looking into the future
Looking into the future

Beyond bispecific antibodies

Beyond bispecific antibodies

previous arrow
next arrow

Erich Hunziker

Dr. Erich Hunziker is the founder and Chairman of the Board of discoveric bio group. He is also Chairman of the Board of Directors of BB Biotech AG. He previously served as CFO of Roche from 2001 to 2010. From 1983 to 2001 he held various executive positions at Corange, Boehringer Mannheim and at Diethelm-Keller-Group (DKSH), where he ultimately served as CEO.

In 2013 he was the seed investor to support EngMab AG, which successfully developed a BCMA-bispecific antibody. EngMab was sold to Celgene in 2016.

Dr. Erich Hunziker is Chairman of Entsia International AG and since July 2019 Chairman of NovImmune/Light Chain Bioscience. He is also a co-founder and Board Member of the LamKap Bio Group.

He earned a Ph.D. in Industrial Engineering from the Swiss Federal Institute of Technology in Zurich.

Erich Hunziker

Back